Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Ankylosing Spondylitis Physical Performance Index (ASPI): objective test for physical functioning is highly reliable and feasible.

van Bentum RE, Ibañez Vodnizza SE, de la Fuente MPP, Valenzuela Aldridge F, Navarro-Compán V, Rusman TR, Ter Wee MM, Valenzuela Letelier O, van Weely SFE, van der Horst-Bruinsma IE.

J Rheumatol. 2020 Feb 1. pii: jrheum.191063. doi: 10.3899/jrheum.191063. [Epub ahead of print]

PMID:
32007935
2.

Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.

Michelsen B, Ørnbjerg LM, Kvien TK, Pavelka K, Nissen MJ, Nordström D, Santos MJ, Koca SS, Askling J, Rotar Z, Gudbjornsson B, Codreanu C, Loft AG, Kristianslund EK, Mann HF, Ciurea A, Eklund KK, Vieira-Sousa E, Yazici A, Jacobsson L, Tomšič M, Löve TJ, Ionescu R, van der Horst-Bruinsma IE, Iannone F, Pombo-Suarez M, Jones GT, Hyldstrup LH, Krogh NS, Hetland ML, Østergaard M.

Rheumatology (Oxford). 2020 Jan 20. pii: kez656. doi: 10.1093/rheumatology/kez656. [Epub ahead of print]

PMID:
31960053
3.

Presence of active MRI lesions in patients suspected of non-radiographic axial spondyloarthritis with high disease activity and chance at conversion after a 6-month follow-up period.

Rusman T, John MB, van der Weijden MAC, Boden BJH, van der Bijl CMA, Bruijnen STG, van der Laken CJ, Nurmohamed MT, van der Horst-Bruinsma IE.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04885-8. [Epub ahead of print]

PMID:
31916108
4.

Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.

Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Mann H, Santos MJ, Reino JG, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, van der Horst-Bruinsma IE, Macfarlane GJ, Iannone F, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML.

Rheumatology (Oxford). 2019 Oct 30. pii: kez427. doi: 10.1093/rheumatology/kez427. [Epub ahead of print]

PMID:
31665497
5.

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.

Al Arashi W, Iñiguez Ubiaga C, Hensor EM, Gaffney K, Freeston J, Vandevelde C, Barr A, van der Horst-Bruinsma I, Marzo-Ortega H.

Rheumatol Adv Pract. 2018 Oct 18;2(2):rky036. doi: 10.1093/rap/rky036. eCollection 2018. No abstract available.

6.

Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.

Ørnbjerg LM, Brahe CH, Askling J, Ciurea A, Mann H, Onen F, Kristianslund EK, Nordström D, Santos MJ, Codreanu C, Gómez-Reino J, Rotar Z, Gudbjornsson B, Di Giuseppe D, Nissen MJ, Pavelka K, Birlik M, Kvien T, Eklund KK, Barcelos A, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Loft AG, van der Horst-Bruinsma I, Jones G, Iannone F, Hyldstrup L, Krogh NS, Hetland ML, Østergaard M.

Ann Rheum Dis. 2019 Nov;78(11):1536-1544. doi: 10.1136/annrheumdis-2019-215427. Epub 2019 Aug 20.

PMID:
31431486
7.

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KA, Landewé RB, Marzo-Ortega H, Navarro-Compán V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X.

Ann Rheum Dis. 2019 Nov;78(11):1550-1558. doi: 10.1136/annrheumdis-2019-215589. Epub 2019 Aug 17.

PMID:
31422357
8.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Aug;78(8):1055-1061. doi: 10.1136/annrheumdis-2018-214877. Epub 2019 Apr 29.

9.

Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.

Ruwaard J, Marsman AF, Nurmohamed MT, van der Horst-Bruinsma IE, Te Velthuis H, Bloem K, de Vries A, Rispens T, Wolbink G.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):756-761. Epub 2019 Mar 18.

10.

Long-Term Treatment With TNF-Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis.

Beek KJ, Rusman T, van der Weijden MAC, Lems WF, van Denderen JC, Konsta M, Visman I, Nurmohamed MT, van der Horst-Bruinsma IE.

J Bone Miner Res. 2019 Jun;34(6):1041-1048. doi: 10.1002/jbmr.3684. Epub 2019 Mar 25.

PMID:
30690799
11.

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis.

Heslinga SC, Konings TC, van der Horst-Bruinsma IE, Kamp O, van Halm VP, de Bruin-Bon H, Peters MJ, Nurmohamed MT.

Biologics. 2018 Nov 8;12:143-149. doi: 10.2147/BTT.S176806. eCollection 2018.

12.

Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.

van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, Kok MR, Schilder AM, Verhoef M, van der Horst-Bruinsma IE.

J Rheumatol. 2019 Feb;46(2):153-159. doi: 10.3899/jrheum.180312. Epub 2018 Nov 1.

13.

First-degree relatives of axial spondyloarthritis patients of the pre-SpA cohort would consider using medication in a preventive setting.

de Winter JJ, de Jong HM, Nieuwkerk PT, van der Horst-Bruinsma IE, Baeten DL, van de Sande MG.

Clin Rheumatol. 2019 Mar;38(3):755-759. doi: 10.1007/s10067-018-4325-6. Epub 2018 Oct 23.

PMID:
30353386
14.

Simultaneous occurrence of ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis: a systematic review.

Kuperus JS, Waalwijk JF, Regan EA, van der Horst-Bruinsma IE, Oner FC, de Jong PA, Verlaan JJ.

Rheumatology (Oxford). 2018 Dec 1;57(12):2120-2128. doi: 10.1093/rheumatology/key211.

PMID:
30060244
15.

Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky.

Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE.

Curr Rheumatol Rep. 2018 May 12;20(6):35. doi: 10.1007/s11926-018-0744-2. Review.

16.

Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance.

Biesbroek PS, Heslinga SC, van de Ven PM, Peters MJL, Amier RP, Konings TC, Maroules CD, Ayers C, Joshi PH, van der Horst-Bruinsma IE, van Halm VP, van Rossum AC, Nurmohamed MT, Nijveldt R.

Clin Rheumatol. 2018 Aug;37(8):2151-2159. doi: 10.1007/s10067-018-4135-x. Epub 2018 May 12.

PMID:
29754182
17.

Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice.

Rusman T, Ten Wolde S, Euser SM, van der Ploeg T, van Hall O, van der Horst-Bruinsma IE.

Int J Rheum Dis. 2018 Apr;21(4):836-842. doi: 10.1111/1756-185X.13271.

18.

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.

Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, Micheroli R, Wildi LM, Zufferey P, Nissen MJ, Villiger PM, Bernhard J, Finckh A, van der Horst-Bruinsma IE, Sieper J, Landewé R, van der Heijde D, Ciurea A; rheumatologists of the Swiss Clinical Quality Management Program.

J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166. Epub 2018 Feb 15.

PMID:
29449504
19.

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography.

Bruijnen STG, Verweij NJF, van Duivenvoorde LM, Bravenboer N, Baeten DLP, van Denderen CJ, van der Horst-Bruinsma IE, Voskuyl AE, Custers M, van de Ven PM, Bot JCJ, Boden BJH, Lammertsma AA, Hoekstra OSH, Raijmakers PGHM, van der Laken CJ.

Rheumatology (Oxford). 2018 Apr 1;57(4):770. doi: 10.1093/rheumatology/key034. No abstract available.

20.

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography.

Bruijnen STG, Verweij NJF, van Duivenvoorde LM, Bravenboer N, Baeten DLP, van Denderen CJ, van der Horst-Bruinsma IE, Voskuyl AE, Custers M, van de Ven PM, Bot JCJ, Boden BJH, Lammertsma AA, Hoekstra OSH, Raijmakers PGHM, van der Laken CJ.

Rheumatology (Oxford). 2018 Apr 1;57(4):631-638. doi: 10.1093/rheumatology/kex448. Erratum in: Rheumatology (Oxford). 2018 Apr 1;57(4):770.

21.

Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.

Ruwaard J, l'Ami MJ, Marsman AF, Kneepkens EL, van Denderen JC, van der Horst-Bruinsma IE, Nurmohamed MT, Wolbink G.

Scand J Rheumatol. 2018 Mar;47(2):122-126. doi: 10.1080/03009742.2017.1330419. Epub 2017 Jul 26.

PMID:
28745108
22.

Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.

Ibáñez Vodnizza SE, Nurmohamed MT, Visman IM, van Denderen JC, Lems WF, Jaime F, van der Horst-Bruinsma IE.

J Rheumatol. 2017 Sep;44(9):1355-1361. doi: 10.3899/jrheum.170094. Epub 2017 Jul 15.

PMID:
28711878
23.

Muscle wasting in male TNF-α blocker naïve ankylosing spondylitis patients: a comparison of gender differences in body composition.

Ibáñez Vodnizza S, Visman IM, van Denderen C, Lems WF, Jaime F, Nurmohamed MT, van der Horst-Bruinsma IE.

Rheumatology (Oxford). 2017 Sep 1;56(9):1566-1572. doi: 10.1093/rheumatology/kex187.

PMID:
28605535
24.

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.

van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J.

Ann Rheum Dis. 2017 Jun;76(6):978-991. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13. Review.

PMID:
28087505
25.

Symptomatic unilateral sacroiliitis as a first presenting feature of IgG4-related disease with successful response to treatment after 1 year of follow-up article.

Jamnitski A, van Hall O, de Vries N, van der Valk P, Lems WF, van der Horst-Bruinsma IE.

Rheumatology (Oxford). 2017 Apr 1;56(4):670-671. doi: 10.1093/rheumatology/kew481. No abstract available.

PMID:
28039416
26.

Insights into cardiac involvement in ankylosing spondylitis from cardiovascular magnetic resonance.

Biesbroek PS, Heslinga SC, Konings TC, van der Horst-Bruinsma IE, Hofman MBM, van de Ven PM, Kamp O, van Halm VP, Peters MJL, Smulders YM, van Rossum AC, Nurmohamed MT, Nijveldt R.

Heart. 2017 May;103(10):745-752. doi: 10.1136/heartjnl-2016-310667. Epub 2016 Nov 16.

PMID:
27852696
27.

Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis.

Cui J, Diogo D, Stahl EA, Canhao H, Mariette X, Greenberg JD, Okada Y, Pappas DA, Fulton RS, Tak PP, Nurmohamed MT, Lee A, Larson DE, Kurreeman F, Deluca TL, O'Laughlin M, Fronick CC, Fulton LL, Mardis ER, van der Horst-Bruinsma IE, Wolbink GJ, Gregersen PK, Kremer JM, Crusius JB, de Vries N, Huizinga TW, Fonseca JE, Miceli-Richard C, Karlson EW, Coenen MJ, Barton A, Plenge RM, Raychaudhuri S.

Arthritis Rheumatol. 2017 Apr;69(4):735-741. doi: 10.1002/art.39966.

28.

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction.

Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE, Krause A, Schmidt R, Schneider M, Sieper J, Andermann B, van Tubergen A, Witt M, Braun J.

RMD Open. 2016 Jul 19;2(2):e000272. doi: 10.1136/rmdopen-2016-000272. eCollection 2016.

29.

Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.

Heldmann F, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):184-90. Epub 2016 Mar 25.

PMID:
27049733
30.

Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.

van Weely SF, Kneepkens EL, Nurmohamed MT, Dekker J, van der Horst-Bruinsma IE.

Arthritis Care Res (Hoboken). 2016 Oct;68(10):1522-9. doi: 10.1002/acr.22869. Epub 2016 Aug 19.

31.

Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study.

van der Weijden MA, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE.

J Rheumatol. 2016 Apr;43(4):758-64. doi: 10.3899/jrheum.150857. Epub 2016 Feb 15.

PMID:
26879348
32.

Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.

Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Ozgocmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M; ASAS.

Ann Rheum Dis. 2016 Jun;75(6):1034-42. doi: 10.1136/annrheumdis-2015-208730. Epub 2016 Feb 10.

PMID:
26865599
33.

Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.

Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KG, Sieper J, Baraliakos X, Bennett A, Braun J, Burgos-Vargas R, Dougados M, Pedersen SJ, Jurik AG, Maksymowych WP, Marzo-Ortega H, Østergaard M, Poddubnyy D, Reijnierse M, van den Bosch F, van der Horst-Bruinsma I, Landewé R.

Ann Rheum Dis. 2016 Nov;75(11):1958-1963. doi: 10.1136/annrheumdis-2015-208642. Epub 2016 Jan 14. Review.

PMID:
26768408
34.

Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients.

Marsman AF, Kneepkens EL, Ruwaard J, Wei JC, Nurmohamed MT, van Denderen C, van der Horst-Bruinsma IE, Rispens T, Wolbink G.

Scand J Rheumatol. 2016 Jul;45(4):331-4. doi: 10.3109/03009742.2015.1114666. Epub 2016 Jan 4. No abstract available.

PMID:
26727457
35.

Reduction of Inflammation Drives Lipid Changes in Ankylosing Spondylitis.

Heslinga SC, Peters MJ, Ter Wee MM, van der Horst-Bruinsma IE, van Sijl AM, Smulders YM, Nurmohamed MT.

J Rheumatol. 2015 Oct;42(10):1842-5. doi: 10.3899/jrheum.150193. Epub 2015 Sep 1.

PMID:
26329334
36.

Implementation of recommended non-pharmacotherapy in rheumatology practice: need for improvement.

van der Linden S, Boonen A, van Tubergen A, Vosse D, Dekker J, Dijkmans B, van der Horst-Bruinsma I, Kapinga T, van der Leeden M, van den Ende C, Hazes JM, Linssen A, Vliet Vlieland T.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1 Suppl 95):S15-7. Epub 2015 Aug 27. No abstract available.

37.

Spine and Rheumatic Diseases.

Wei JC, Liu Y, Tsou HK, van der Horst-Bruinsma IE.

Biomed Res Int. 2015;2015:756205. doi: 10.1155/2015/756205. Epub 2015 Jul 28. No abstract available.

38.

Study on the protective effect of the KIR3DL1 gene in ankylosing spondylitis.

Vendelbosch S, Heslinga SC, John M, van Leeuwen K, Geissler J, de Boer M, Tanck MW, van den Berg TK, Crusius JB, van der Horst-Bruinsma IE, Kuijpers TW.

Arthritis Rheumatol. 2015 Nov;67(11):2957-65. doi: 10.1002/art.39288.

39.

Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.

Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Compán V, L'Ami M, Nurmohamed MT, van der Horst-Bruinsma I, Jurado T, Diego C, Bonilla G, Villalba A, Peiteado D, Nuño L, van der Kleij D, Rispens T, Martín-Mola E, Balsa A, Pascual-Salcedo D.

J Rheumatol. 2015 Sep;42(9):1638-46. doi: 10.3899/jrheum.141128. Epub 2015 Jul 15.

PMID:
26178279
40.

Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.

Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, Ward M, Gensler LS, Zhou X, Garchon HJ, Chiocchia G, Nossent J, Lie BA, Førre Ø, Tuomilehto J, Laiho K, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Haroon N, Mulero J, Blanco FJ, Gonzalez-Gay MA, Lopez-Larrea C, Bowness P, Gaffney K, Gaston H, Gladman DD, Rahman P, Maksymowych WP, Crusius JB, van der Horst-Bruinsma IE, Valle-Oñate R, Romero-Sánchez C, Hansen IM, Pimentel-Santos FM, Inman RD, Martin J, Breban M, Wordsworth BP, Reveille JD, Evans DM, de Bakker PI, Brown MA.

Nat Commun. 2015 May 21;6:7146. doi: 10.1038/ncomms8146.

41.

ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients.

Robinson PC, Costello ME, Leo P, Bradbury LA, Hollis K, Cortes A, Lee S, Joo KB, Shim SC, Weisman M, Ward M, Zhou X, Garchon HJ, Chiocchia G, Nossent J, Lie BA, Førre Ø, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu X, Elewaut D, Burgos-Vargas R, Gensler LS, Stebbings S, Haroon N, Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay MA, Lopez-Larrea C, Bowness P, Gafney K, Gaston JS, Gladman DD, Rahman P, Maksymowych WP, Xu H, van der Horst-Bruinsma IE, Chou CT, Valle-Oñate R, Romero-Sánchez MC, Hansen IM, Pimentel-Santos FM, Inman RD, Martin J, Breban M, Evans D, Reveille JD, Kim TH, Wordsworth BP, Brown MA.

Ann Rheum Dis. 2015 Aug;74(8):1627-9. doi: 10.1136/annrheumdis-2015-207416. Epub 2015 Apr 27. No abstract available.

42.

Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation.

Heslinga SC, Van den Oever IA, Van Sijl AM, Peters MJ, Van der Horst-Bruinsma IE, Smulders YM, Nurmohamed MT.

BMC Musculoskelet Disord. 2015 Apr 9;16:80. doi: 10.1186/s12891-015-0532-3.

43.

C-reactive protein polymorphisms influence serum CRP-levels independent of disease activity in ankylosing spondylitis.

Claushuis TA, de Vries MK, van der Weijden MA, Visman IM, Nurmohamed MT, Twisk JW, Van der Horst-Bruinsma IE, Crusius JB.

Clin Exp Rheumatol. 2015 Mar-Apr;33(2):159-65. Epub 2015 Jan 20.

PMID:
25603416
44.

Objective evaluation of physical functioning after tumor necrosis factor inhibitory therapy in patients with ankylosing spondylitis: a selection of 3 feasible performance-based tests.

van Weely SF, Dekker J, Steultjens MP, van Denderen JC, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE.

J Rheumatol. 2015 Apr;42(4):623-9. doi: 10.3899/jrheum.140337. Epub 2015 Jan 15.

PMID:
25593234
45.

Adverse effects of TNF inhibitors in SpA: are they different from RA?

Sampaio-Barros PD, van der Horst-Bruinsma IE.

Best Pract Res Clin Rheumatol. 2014 Oct;28(5):747-63. doi: 10.1016/j.berh.2014.10.001. Epub 2014 Oct 31. Review.

PMID:
25488782
46.

[Spondyloarthritis: new names for old acquaintances].

van der Horst-Bruinsma IE.

Ned Tijdschr Geneeskd. 2014;158:A7820. Review. Dutch.

PMID:
25351383
47.

Problems in work participation and resource use should not be underestimated in patients with early spondyloarthritis.

van der Weijden MA, Boonen A, van der Horst-Bruinsma IE.

J Rheumatol. 2014 Dec;41(12):2413-20. doi: 10.3899/jrheum.140396. Epub 2014 Oct 15.

PMID:
25320217
48.

Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis.

Robinson PC, Claushuis TA, Cortes A, Martin TM, Evans DM, Leo P, Mukhopadhyay P, Bradbury LA, Cremin K, Harris J, Maksymowych WP, Inman RD, Rahman P, Haroon N, Gensler L, Powell JE, van der Horst-Bruinsma IE, Hewitt AW, Craig JE, Lim LL, Wakefield D, McCluskey P, Voigt V, Fleming P; Spondyloarthritis Research Consortium of Canada, Australio-Anglo-American Spondylitis Consortium, International Genetics of Ankylosing Spondylitis Consortium, Wellcome Trust Case Control Study 2, Mariapia Degli-Esposti, Degli-Esposti M, Pointon JJ, Weisman MH, Wordsworth BP, Reveille JD, Rosenbaum JT, Brown MA.

Arthritis Rheumatol. 2015 Jan;67(1):140-51. doi: 10.1002/art.38873.

49.

The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns.

Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst-Bruinsma IE, Inman RD, Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman MH, Landewé RB.

Arthritis Rheumatol. 2014 Oct;66(10):2649-56. doi: 10.1002/art.38776. No abstract available.

50.

Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis.

van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE.

J Rheumatol. 2014 Sep;41(9):1843-8. doi: 10.3899/jrheum.131289. Epub 2014 Aug 1.

PMID:
25086071

Supplemental Content

Loading ...
Support Center